Mavyret and Januvia drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mavyret (glecaprevir; pibrentasvir) and Januvia (sitagliptin phosphate). Common drug interactions include angioedema among females and headache among males.

The phase IV clinical study analyzes what interactions people have when they take Mavyret and Januvia. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Mavyret?

Mavyret has active ingredients of glecaprevir; pibrentasvir. eHealthMe is studying from 10,533 Mavyret users. Check the latest studies of Mavyret.

What is Januvia?

Januvia has active ingredients of sitagliptin phosphate. It is often used in diabetes. eHealthMe is studying from 72,818 Januvia users. Check the latest studies of Januvia.



On Jul, 04, 2026

17 people who take Mavyret and Januvia together, and have interactions are studied.

Mavyret and Januvia drug interactions.

What are the common drug interactions of Mavyret and Januvia, by gender? *:

female:

  1. Angioedema (rapid swelling of the dermis)
  2. Abdominal distension
  3. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  4. Fatigue (feeling of tiredness)
  5. Leukaemic lymphoma (a rare cancer of the immune systems own t-cells)
  6. Asthenia (weakness)
  7. Blood glucose decreased
  8. Chest pain
  9. Decreased appetite
  10. Dizziness

male:

  1. Headache (pain in head)
  2. Asthenia (weakness)
  3. Chills (felling of cold)
  4. Dysplasia (enlargement of an organ or tissue)
  5. Gallbladder operation
  6. Gastric ulcer (stomach ulcer)
  7. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  8. Gastrointestinal inflammation (inflammation of stomach and intestine)
  9. General physical health deterioration (weak health status)
  10. Influenza like illness

What are the common drug interactions of Mavyret and Januvia, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Abdominal distension
  2. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  3. Fatigue (feeling of tiredness)
  4. Leukaemic lymphoma (a rare cancer of the immune systems own t-cells)
  5. Asthenia (weakness)
  6. Chills (felling of cold)
  7. Gastric ulcer (stomach ulcer)
  8. Gastrointestinal inflammation (inflammation of stomach and intestine)
  9. Influenza like illness
  10. Oesophageal stenosis (narrowing of oesophagus)

60+:

  1. Angioedema (rapid swelling of the dermis)
  2. Colon adenoma (non cancerous epithelial colon tumour having a glandular origin and structure)
  3. Fall
  4. Gallbladder operation
  5. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  6. General physical health deterioration (weak health status)
  7. Hip fracture
  8. Hospitalisation
  9. Intestinal ulcer
  10. Large intestinal ulcer

What are the existing conditions these people have? *

  1. Hepatitis C: 9 people, 52.94%
  2. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 5.88%
  3. Neuritis (inflammation of nerve): 1 person, 5.88%
  4. Muscle Aches (muscle pain): 1 person, 5.88%
  5. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.88%
  6. Insomnia (sleeplessness): 1 person, 5.88%
  7. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.88%
  8. High Blood Pressure: 1 person, 5.88%
  9. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.88%
  10. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Mavyret and Januvia?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Mavyret and Januvia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mavyret:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Januvia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mavyret and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Januvia and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on glecaprevir; pibrentasvir and sitagliptin phosphate (the active ingredients of Mavyret and Januvia, respectively), and Mavyret and Januvia (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: